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Abstract
In patients with typical angina pectoris, inducible myocardial ischaemia and
macroscopically normal coronaries (cardiac syndrome X (CSX)), a significantly
elevated plasma level of terminal complement complex (TCC), the common end
product of complement activation, has been observed without accompanying
activation of the classical or the alternative pathways. Therefore, our aim was to
clarify the role of the ficolin–lectin pathway in CSX. Eighteen patients with
CSX, 37 stable angina patients with significant coronary stenosis (CHD) and 54
healthy volunteers (HC) were enrolled. Serum levels of ficolin-2 and ficolin-3,
ficolin-3/MASP-2 complex and ficolin-3-mediated TCC deposition (FCN3-TCC)
were determined. Plasma level of TCC was significantly higher in the CSX than
in the HC or CHD group (5.45 versus 1.30 versus 2.04 AU/ml, P < 0.001).
Serum levels of ficolin-2 and ficolin-3 were significantly lower in the CSX
compared to the HC or CHD group (3.60 versus 5.80 or 5.20 lg/ml, P < 0.05;
17.80 versus 24.10 or 26.80 lg/ml, P < 0.05). The ficolin-3/MASP-2 complex
was significantly lower in the CSX group compared to the HC group (92.90
versus 144.90 AU/ml, P = 0.006). FCN3-TCC deposition was significantly
lower in the CSX group compared to the HC and CHD groups (67.8% versus
143.3% or 159.7%, P < 0.05). In the CSX group, a significant correlation was
found between TCC and FCN3-TCC level (r = 0.507, P = 0.032) and between
ficolin-3/MASP-2 complex level and FCN3-TCC deposition (r = 0.651,
P = 0.003). In conclusion, in patients with typical angina and myocardial
ischaemia despite macroscopically normal coronary arteries, low levels of several
lectin pathway parameters were observed, indicating complement activation and
consumption. Complement activation through the ficolin–lectin pathway might
play a role in the complex pathomechanism of CSX.
Introduction
Our understanding of coronary syndromes has evolved in
the last two decades from the paradigm of obstructive
atherosclerosis of epicardial coronary arteries into the
complex concept of anatomo-functional abnormalities of
coronary microcirculation. Under normal physiological
conditions, the coronary microcirculation regulates
myocardial perfusion in response to increased demand by
endothelial-dependent and endothelial-independent mech-
anisms [1].
Patients with typical angina pectoris and inducible
myocardial ischaemia, but with macroscopically healthy
coronaries has became commonly known as ‘cardiac
syndrome X’ (CSX, with incidence of 19% in men and
up to 48% in women) [2, 3]. As an underlying
pathomechanism, microvascular angina characterized by
reduced coronary microvascular dilatory responses and
increased coronary resistance has been suggested and
consistently found in patients with CSX [4]. In stable
angina patients with proven myocardial ischaemia and
normal coronary arteries, significantly increased risks of
future major adverse cardiac events and all-cause mortality
were found compared to a normal population without
ischaemic heart disease, even after adjusting for traditional
cardiac risk factors [3, 4]. Although obvious explanation –
namely endothelial dysfunction and other microvascular
abnormalities in both coronary and peripheral arteries – has
been suggested a decade ago, the complex pathomechanism
has remained undetermined [5–8]. Taken together, stable
angina patients with normal coronary arteries should be
recognized as a unique clinical entity [9].
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Data about the role of complement system in angina
patients with macroscopically normal coronary arteries are
lacking. As previously published [10], the level of terminal
soluble C5b-9 complex (TCC) was increased in plasma of
this patient group compared to those with angiographically
proven coronary atherosclerosis. In these patients, despite
the lacking morphologically evident atherosclerotic lesions,
complement system activation seems to be present.
The complement system can be activated via three
different routes, namely by the classical, the alternative or
the lectin pathway [11, 12]. The lectin pathway is
triggered by the binding of mannose-binding lectin
(MBL) or ficolins to special carbohydrate structures on
the surface of micro-organisms, apoptotic cells or altered-
self structures [13]. In humans, five initiation molecules of
the lectin pathway have been described: MBL, the recently
recognized ficolin-1 (M-ficolin), ficolin-2 (L-ficolin), fico-
lin-3 (H-ficolin or Hakata antigen) and lately also
collectin-11 [14–16]. While ficolin-1 can be predomi-
nantly found intracellularly in leucocytes, ficolin-2 and
ficolin-3 can be found mainly in serum [17]. MBL and
ficolins in serum are complexed with MBL/ficolin-
associated serine proteases (MASPs – i.e. MASP-1,
MASP-2 or MASP-3) and their truncated proteins (sMAP
and MAP-1) [16, 18, 19]. The initiation of the lectin
pathway finally results in the formation of terminal
pathway activation complex (TCC or C5b-9), similar to
the previously mentioned classical or alternative pathways.
Importantly, MASPs can activate C4 and C2 leading to the
generation of C3 convertase (C4b2b) of the complement
classical and lectin pathways [13, 19].
As we published previously [10], the high C1rC1sC1-
INH level (observed in patients with significant coronary
atherosclerosis) was an independent biomarker of ischaemic
heart disease. In this study, the level of TCC was increased
in patients with macroscopically healthy coronary arteries
compared to those with angiographically proven coronary
atherosclerosis. As no parallel activation of the classical or
the alternative complement pathway was observed in this
study, our findings indicated the potential involvement of
the lectin pathway in the CSX patient population. Based
on these results, our aim was to clarify the role of lectin
pathway activation and ficolins in the CSX patient cohort.
Materials and methods
Patient population. In this case–control study, we enrolled
55 patients scheduled for elective coronary angiography at
our institution with diagnosis of stable angina pectoris. In
each patient, non-invasive tests (exercise stress test or
myocardial perfusion scan) were performed before coronary
angiography and were positive for inducible myocardial
ischaemia. The coronary angiography showed macroscop-
ically normal coronary arteries, despite the history of
typical angina and positive ischaemia provocation non-
invasive tests in 18 patients (CSX group). In 37 patients,
angiography indicated significant coronary artery stenosis
(coronary heart disease: CHD group). These patients were
referred to percutaneous coronary intervention or to
coronary artery bypass graft (CABG) surgery or were
advised for conservative therapy. The cohort of patients
with stable angina was examined in a previous study,
determining the classical and alternative pathways of
complement activation [10]. Fifty-four healthy volunteers
served as controls (HC group).
Blood samples. In each patient, 8 ml of venous blood was
drawn from the cubital vein into serum-separating tubes
before coronary angiography. Peripheral blood samples
were drawn from healthy subjects similarly. The serum was
separated by centrifugation at 3000 rpm for 10 min at
room temperature. The samples were immediately frozen at
80 °C in aliquots and were thawed only before the
measurement of lectin pathway parameters. Patient exclu-
sion criteria were as follows: acute coronary syndrome,
cardiogenic shock, history of severe renal or hepatic disease,
haematological disorders, acute or chronic inflammatory
disease and malignancy. The study protocol was approved
by both the institutional review board of Semmelweis
University of Budapest and the Hungarian Defence Forces
Medical Centre. Informed consent was obtained in accor-
dance with the Declaration of Helsinki.
Measurement of the lectin pathway parameters. The concen-
trations of ficolin-2 [20], ficolin-3 [21], the ficolin-3/
MASP-2 complex [22], MAP-1 [23] and sC5b-9 (TCC) [10]
were determined by previously described standard sand-
wich ELISA techniques, using monoclonal antibodies
specific for each molecule. Biotinylated antibodies were
added to the second layer, and streptavidin/HRP com-
plexes were used for detection. All samples were tested in
duplicate against a standard serum pool with known
content of each analyte. Ficolin-3-mediated terminal
complement complex deposition (FCN3-TCC) was mea-
sured as described previously by Hein et al. [24]. In brief,
acetylated bovine serum albumin (acBSA) was immobilized
in Maxisorp ELISA plates and used as a ficolin-3 ligand. To
block any interference from the classical pathway or the
alternative pathway [25], full serum samples were pre-
incubated with sodium polyanethol sulphonate (SPS).
Serum samples were diluted 1:25 in barbital buffer
containing 0.05% Tween-20 (VBS-T) and incubated on
the plate for 45 min at 37 °C. Thereafter, mouse anti-
human TCC was applied for 2 h at room temperature, and
then, rabbit anti-mouse HRP was added to the wells as
secondary antibody, for 1 h at 37 °C. Finally, the plates
were developed using OPD substrate, and the optical
density was determined at 490/630 nm by ELISA reader
(BioTek).
Statistical analysis. The statistical calculations were
performed with PRISM for Windows v5.02 (GraphPad
Software Inc., San Diego, CA, USA; www.graphpad.com)
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and SPSS v13.0 (SPSS Inc., Chicago, IL, USA). As most of
the variables were non-Gaussian, nonparametric tests were
applied. Mann–Whitney U-test was used to compare two
independent groups. Spearman rank correlation analysis
was performed to analyse correlation between continuous
variables. All the statistical analyses were two-tailed, and
P < 0.05 was considered to represent a significant differ-
ence.
Results
Demographic data
Demographic data of the CSX and CHD populations are
presented in Table 1. The 54 healthy volunteers (21 men
and 33 women, median age: 33 years, 25–75th percentiles:
21–58 years) did not have any known disease. Within the
healthy control group, age and BMI (P < 0.0001 for both
comparisons) were significantly lower, compared to the
CSX and CHD groups, respectively.
Both patient groups had increased presence of conven-
tional cardiovascular risk factors, such as hypertension, type
2 diabetes mellitus, hyperlipidaemia, obesity, previous
cardiovascular event and tobacco use. The majority of the
patients received antiplatelet therapy, ACE inhibitor, beta-
blocker, statin or nitrate. No significant difference was
found regarding medical therapy upon admission between
patient groups (Table 1). Compared to patients with CSX,
a significantly higher incidence of previous myocardial
infarction (P = 0.003, Fisher’s exact test) and percutaneous
coronary intervention (P = 0.003, Fisher’s exact test) was
observed in the CHD group. Interestingly, there were no
significant differences in body mass index; both groups
were in the ‘overweight’ category. The HDL-cholesterol
level was significantly higher in patients with CSX,
compared to patients with CHD (P = 0.013, Mann–
Whitney U-test).
When comparing the laboratory parameters, we found
no significant differences in kidney or liver function
parameters between the patient groups.
Serum and plasma levels of lectin pathway components
The plasma level of TCC, the common end product of the
complement activation pathways, was significantly higher
in the CSX group compared to the CHD and HC groups
(5.45 AU/ml versus 2.04 AU/ml, P = 0.0001; 5.45 AU/
ml versus 1.30, P < 0.0001) (Table 2). These data repre-
sent a subgroup analysis of our previously published results
[10].
The serum levels of ficolin-2 were significantly lower in
the CSX group compared to the HC group (3.60 lg/ml
versus 5.80 lg/ml, P = 0.005) and also lower compared to
the CHD group (3.60 lg/ml versus 5.20 lg/ml,
P = 0.052). Similarly, the serum levels of ficolin-3 were
significantly lower in the CSX group compared to the HC
group (17.80 lg/ml versus 24.10 lg/ml, P = 0.035) and
CHD (17.80 lg/ml versus 26.80 lg/ml, P = 0.016)
group, as well (Table 2).
The ficolin-3/MASP-2 complex was significantly lower
in the CSX group compared to the HC group (92.90 AU/
ml versus 144.90 AU/ml, P = 0.006). Interestingly, the
ficolin-3/MASP-2 complex was also significantly lower in
the CHD group compared to the HC group (87.0 AU/ml
versus 144.90 AU/ml, P = 0.011).
The FCN3-TCC deposition was significantly lower in
the CSX group compared to the HC group (67.8% versus
143.3%, P = 0.008) and the CHD (67.8% versus 159.7%,
P = 0.037) group, as well. There were no significant
differences in serum MAP-1 levels; however, the levels
tended to be the lowest in the CSX group (CSX:
178.60 ng/ml, HC: 194.50 ng/ml, CHD: 212.40 ng/ml)
(Table 2).
Correlations between serum lectin pathway parameters in the
CSX group
We found a significant correlation between TCC and
FCN3-TCC in the CSX group (r = 0.507, P = 0.032)
(Fig. 1A). Similarly, the ficolin-3/MASP-2 complex level
and FCN3-TCC deposition correlated significantly
(r = 0.651, P = 0.003) (Fig. 1B).
Cardiovascular risk factors and serum lectin pathway
components
When analysing the whole patient cohort (n = 55), a
significantly higher TCC level (5.04 AU/ml versus
2.05 AU/ml, P = 0.0002) was observed in non-smoking
individuals compared to smoking patients. Presence of
hypertension or diabetes mellitus, similar to age, body
mass index, kidney and liver function parameters and CRP,
was not associated with the measured lectin pathway
parameters.
Importantly, among cardiovascular risk factors, patients
with hyperlipidaemia had significantly different levels of
lectin pathway products. Ficolin-2, ficolin-3, ficolin-3/
MASP-2 complex and FCN3-TCC deposition were signif-
icantly higher in hyperlipidaemic CHD patients (Table 3).
Remarkably, this phenomenon was not observed in the
CSX group (Table 3).
Further evaluating hyperlipidaemic patients, we anal-
ysed the serum lectin pathway parameters with respect to
serum cholesterol and triglyceride levels. When Spearman
rank test was performed, serum lectin pathway component
levels showed no significant correlation with serum
cholesterol values. In contrast, we found a significant
correlation with ficolin-2, ficolin-3, ficolin-3/MASP-2
complex, FCN3-TCC deposition and MAP-1 levels and
serum triglyceride levels in the CHD group (Table 4). It is
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Table 1 Demographic parameters.
Demographic data CHD (n = 37) CSX (n = 18) HC (n = 54)
Age, mean  SD, years 61.44  8.69 61.08  8.81 35.00  11.25a
Males/females, n (%) 32 (86.4)/5 (13.6) 9 (50)/9 (50) 21 (39)/33 (61)c
BMI, mean  SD, kg/m2 29.06  5.61 28.56  4.73 23.69  4.60a
Risk factors
History of tobacco use, n (%) 28 (75.6) 8 (44.4) 6 (11.1)a
Hypertension, n (%) 32 (86.4) 14 (77.7) 5 (9.26)a
Diabetes mellitus, n (%) 17 (45.9) 3 (16.6) 0 (0)a
Hyperlipidaemia, n (%) 17 (45.9) 7 (38.8) 2 (3.70)a
Previous AMI, n (%) 18 (48.6)b 0 (0) 0 (0)
Previous PCI, n (%) 19 (51.3)b 0 (0) 0 (0)
Previous CABG, n (%) 6 (16.2)b 0 (0) 0 (0)
Medication on admission
Aspirin, n (%) 26 (70.27) 9 (50) 2 (3.70)a
Clopidogrel, n (%) 25 (67.6) 5 (27.7) 0 (0)a
ACE inhibitors, n (%) 31 (83.7) 11 (29.7) 1 (1.85)a
Beta-blockers, n (%) 34 (91.9) 15 (83.3) 1 (1.85)a
Lipid-lowering agents, n (%) 32 (86.4) 9 (50) 0 (0)a
Nitroglycerine/nitrates, n (%) 9 (24.3) 5 (27.7) 0 (0)a
Laboratory parameters
CK, mean  SD (U/l) 136.94  58.63 101.40  44.40 n.m.
LDH, mean  SD (U/l) 335.23  63.93 268.36  139.51 n.m.
Cholesterol, mean  SD (mmol/l) 4.15  1.03 4.66  1.31 4.84  0.88c
HDL-cholesterol, mean  SD (mmol/l) 0.98  0.20b 1.29  0.41 1.55  0.59
LDL-cholesterol, mean  SD (mmol/l) 2.44  0.90 2.53  0.94 2.57  0.96
Triglycerides, mean  SD (mmol/l) 1.58  0.71 1.56  0.72 0.95  1.01c
GOT, mean  SD (U/l) 25.75  11.29 31.18  19.45d 20.00  5.46
Creatinine, mean  SD (lmol/l) 74.87  14.70 78.83  21.23 67.00  12.29c
CN, mean  SD (mmol/l) 5.66  1.46 6.66  2.42 4.40  1.02a
CRP, mean  SD (mg/l) 3.16  2.23 2.49  2.83 n.m.
Fructosamine, mean  SD (lmol/l) 233.82  41.96 236.88  32.57 n.m.
SD, standard deviation; CHD, patients with coronary heart disease; CSX, patients with negative coronary angiography; HC, healthy control individuals;
BMI, body mass index; CK, creatine kinase; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; CN, carbamide; n.m., not measured.
The values in parentheses represent percentages. Values are means  SD or n (%).
Fisher’s exact test for the categorical variables and Mann–Whitney test for the continuous variables. Individuals in the HC group received ASA and statin
for primary prevention of cardiovascular events.
aSignificant differences in HC group compared to CSX and CHD groups, P < 0.01 respectively.
bSignificant differences in CHD group compared to CSX and HC groups, P < 0.05 respectively.
cSignificant differences between CHD versus HC group, P < 0.05.
dSignificant differences between CSX versus HC group, P < 0.05.
Table 2 Serum lectin pathway parameter levels in the patient groups (CHD and CSX) and healthy controls (HC).
CHD CSX HC P value
TCC, AU/ml 2.04 (1.54–2.46) 5.45 (3.71–7.62) 1.30 (0.93–2.29) 0.0001a
<0.0001b
Ficolin-2, lg/ml 5.20 (3.50–7.70) 3.60 (3.20–4.70) 5.80 (4.20–8.0) 0.052a
0.005b
Ficolin-3, lg/ml 26.80 (18.30–37.10) 17.80 (12.90–25.30) 24.10 (18.20–30.10) 0.016a
0.035b
MAP-1, ng/ml 212.40 (169.80–237.60) 178.60 (123.40–253.60) 194.50 (149.60–279.50) NS
Ficolin-3/MASP-2 complex, AU/ml 87.0 (54.90–188.60) 92.90 (39.40–121.70) 144.90 (89.80–336.20) 0.506a
0.006b
Ficolin-3-mediated TCC deposition, % 159.70 (72.70–203.0) 67.80 (27.80–129.0) 143.30 (91.90–195.30) 0.037a
0.008b
CHD, patients with coronary heart disease; CSX, patients with cardiac syndrome X.
The values in parentheses represent 25–75th percentile. Values are given as medians.
aCHD versus CSX.
bCSX versus HC.
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important to note that such correlations were absent in the
CSX group.
Medical therapy and serum lectin pathway parameters
Intake of acetylsalicylic acid, ACE inhibitors, beta-blockers
and lipid-lowering agents was not associated with the
measured lectin pathway parameters (data not shown).
Patients on chronic clopidogrel therapy had signifi-
cantly higher ficolin-3/MASP-2 complex (121.67 AU/ml
versus 73.50 AU/ml, P = 0.015) and ficolin-3 (30.40 lg/
ml versus 16.60 lg/ml, P = 0.006) levels in the CSX
subgroup, when compared to patients without such
therapy. Similar phenomenon was not observed in the
CHD group.
Discussion
Cardiac syndrome X remains a major diagnostic and
therapeutic challenge causing significant deterioration in
patient’s functioning and quality of life. Although sub-
stantial data report microvascular and endothelial dysfunc-
tion within this patient group, the complex
pathomechanism is still unclear.
In the present study, we have demonstrated consump-
tion of multiple parameters along the ficolin–lectin
pathway. We observed significantly lower serum levels of
ficolin-2, ficolin-3, ficolin-3/MASP-2 complex and FCN3-
TCC deposition accompanied by significantly higher TCC
level in patients with CSX compared to healthy controls
and to patients with angiographically proven coronary
heart disease. Furthermore, we found significant correla-
tions between TCC and FCN3-TCC deposition and
between ficolin-3/MASP-2 complex level and FCN3-TCC
deposition.
According to these results, in the group of patients with
CSX, consumption and activation of the ficolin–lectin
pathway are present, best marked by low levels of ficolin-2
and ficolin-3. We consider lower ficolin-3/MASP-2 com-
plex levels as a consequence of the decreased level of the
ficolin-3 component. Measurement of the FCN3-TCC,
where the serum is activated with a ficolin-3 specific
activator agent and the induced TCC formation is analysed,
is indicative of the remaining activity of the pathway.
Decreased ficolin-3-mediated TCC deposition is therefore a
sign of prior in vivo activation and consumption of the
ficolin–lectin pathway.
Lectin pathway activation appears to have a contro-
versial role in the cardiovascular system. While several
studies pointed to a beneficial effect of the lectin
pathway activation resulting in antiatherosclerotic effect
[26, 27], others showed adverse cardiovascular effects of
high MBL plasma concentration [28]. MASPs were
associated with cardiovascular risk factors including
Figure 1 Correlations between serum lectin pathway components in the
CSX group. (A) Correlation between TCC and FCN3-TCC in the CSX
group. (B) Correlation between ficolin-3/MASP-2 complex level and
FCN3-TCC deposition.
Table 3 Serum lectin pathway component levels according to the
presence/absence of hyperlipidaemia.
CHD CSX
HL +/HL  HL +/HL 
C5b-9, AU/ml 2.05/2.03 5.80/5.10
Ficolin-3-mediated
TCC deposition, %
170.50/81.60 (0.003) 77.30/51.60
Ficolin-3/MASP-2
complex, AU/ml
132.60/72.02 (0.013) 94.40/88.0
Ficolin-2 lg/ml 6.90/4.60 (0.047) 3.50/3.60
Ficolin-3 lg/ml 34.30/18.40 (0.0001) 19.0/16.70
MAP-1 ng/ml 227.90/207.70 185.0/171.0
HL, hyperlipidaemia; CHD, patients with coronary heart disease; CSX,
patients with cardiac syndrome X.
The values in parentheses represent P value. Values are given as medians.
Table 4 Correlation between serum lectin pathway parameter levels and
serum triglyceride levels in different patient subgroups.
Correlation between
serum triglyceride
levels and: CHD CSX
sC5b-9 R = 0.086/P = 0.691 R = 0.414/P = 0.098
Ficolin-3-mediated
TCC deposition
R = 0.424/P = 0.043 R = 0.098/P = 0.737
Ficolin-3/MASP-2
complex
R = 0.426/P = 0.042 R = 0.143/P = 0.626
Ficolin-2 R = 0.528/P = 0.009 R = 0.055/P = 0.851
Ficolin-3 R = 0.512/P = 0.012 R = 0.200/P = 0.493
MAP-1 R = 0.449/P = 0.031 R = 0.402/P = 0.154
CHD, patients with coronary heart disease; CSX, patients with cardiac
syndrome X.
Values represent the results of Spearman rank correlation analysis.
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dyslipidaemia, obesity and hypertension in patients with
stable coronary artery disease [29]. Furthermore, MASP-2
plasma level was lower in myocardial infarction and
stroke patients compared to patients with stable coronary
artery disease [29]. In a magnetic resonance study,
ficolin-2, MBL and MAP-1 were associated with left
ventricle dilatation after myocardial infarction, indicating
a potential role for lectin pathway products in myocar-
dial remodelling [30].
Although our results suggest changes in lectin pathway
complement cascade in patients with CSX, our data cannot
verify the causality between the measured parameters and
pathogenesis of CSX. There is a general agreement that the
main pathological feature in the majority of patients with
CSX is microvascular/endothelial dysfunction [31]. Dollard
et al. [32] demonstrated that C-reactive protein (CRP)
remains significantly higher in patients with CSX who
remain symptomatic than in either healthy controls.
Furthermore, coronary endothelial dysfunction may be
associated with an increased release of constricting factors
and the production of pro-inflammatory cytokines, cell
adhesion molecules and growth factors (i.e. intracellular
cell adhesion molecule-1 and vascular cell adhesion
molecule-1). Inflammatory and proliferative changes in
the vessel wall might cause arteriole hyperplasia and
perivascular fibrosis leading to microvascular dysfunction
[33–35].
Several members of the complement system were
found to be deposited in the microvascular system of
patients with diabetes (glomeruli and glomerular capil-
laries [36], retinal vessels [37] and choriocapillaris [38]).
Based on our findings, namely the significantly lower
serum levels of ficolin-2 and ficolin-3 and the ficolin-3/
MASP-2 complex, we hypothesize that lectin pathway
product deposition might also occur in the subendothe-
lial matrix and contribute to microvascular dysfunction.
Besides, these activated molecules might bind to patho-
logical structures on the surface of endothelial cells. It
was described that ficolins recognize acetyl-group-
containing substances including N-acetylglucosamine
[39, 40] and glucan [41]. Furthermore, in addition to
sugars, they also could bind to substances such as elastin
and DNA [18]. An intact endothelium is a fully
biocompatible surface that is not recognized by the
complement system. However, blood contact with a
damaged endothelium will lead to a certain degree of
activation of the complement system [42].
The end product of the complement activation, com-
posed of components C5b, C6, C7, C8 and C9, called
terminal complement complex C5b-9 (TCC), or ‘mem-
brane attack complex’ (MAC). TCC facilitates the killing
of bacteria and other pathogens by altering the perme-
ability of their membranes. TCC was initially considered
to be involved mainly in cytolytic processes of either
pathogenesis or host cells [11]. Endothelial cells represent a
potential target of TCC, which exerts a number of non-
cytolytic effects [43]. Hoffmeister et al. [44] described
elevated C5b-9 levels in patients with stable angina
compared to healthy individuals. Furthermore, in patients
with acute coronary syndromes the C5b-9 levels were even
higher [44]. Our data are in agreement with these
observations; TCC levels were lowest in healthy controls
and significantly elevated in the CHD group. Interest-
ingly, TCC levels were the highest in patients with CSX.
Excess amount of this membrane attack complex might
have a direct cytolytic effect on endothelial cells, con-
tributing to the well-documented above-described
endothelial dysfunction in these patients.
There are several potential triggers of microvascular
dysfunction, including many of the conventional cardiac
risk factors such as hypertension, dyslipidaemia and
smoking [45]. Triglyceride levels correlated significantly
with all the lectin pathway components in patients with
CHD but not in patients with CSX. One can speculate that
the well-known relationship between high serum lipid
levels, lipid accumulation and atherosclerotic plaques is
absent in these patients.
Emerging evidence suggests that platelets may have an
ability to interact with both the classical and alternative
pathways of complement activation [46]. Our results
indicate that medical therapy with the platelet ADP
receptor inhibitor clopidogrel was associated with the lack
of ficolin–lectin pathway consumption in patients with
CSX. Clopidogrel has a pleiotropic, anti-inflammatory and
immune response/modulating effect and might influence
the lectin pathway of the complement system as well.
However, low number of individuals on chronic clopido-
grel therapy in the CSX cohort was inadequate to further
analyse the complex effect.
MBL, similar to ficolins, is a pattern recognition
molecule and is an upstream component of the lectin
pathway complement cascade [11, 12]. High level of MBL
was found in ST-elevation myocardial infarction patients
with reduced left ventricular systolic function [47].
Elevated MBL level was shown to be a risk factor for
future development of coronary heart disease in healthy
men [28]. In contrast, in a large prospective study high
MBL level was associated with decreased risk of myocar-
dial infarction independently of other cardiovascular
factors [48]. Furthermore, MBL deficiency-associated
genotypes were linked to increased early incidence of
myocardial infarction [49]. Taken together, the role of
MBL in the development of cardiovascular disease and/or
prognosis is controversial, and data regarding angina
patients with macroscopically normal coronaries are
completely missing. In the future, determination of the
MBL level might be relevant in patients with cardiac
syndrome X.
In summary, we demonstrate significantly lower serum
levels of lectin pathway parameters, namely ficolin-2,
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ficolin-3, ficolin-3/MASP-2 complex and FCN3-TCC
deposition, and significantly higher TCC levels in patients
with CSX compared to healthy controls or to patients with
angiographically proven coronary heart disease. Low levels
of several lectin pathway products might reflect upstream
consumption and consequent, downstream terminal com-
plement complex activation. As we hypothesized, comple-
ment activation might contribute to the increased
cardiovascular risk of patients with CSX by promoting
endothelial and microvascular dysfunction. The topic of
complement system activation via the lectin pathway
requires further evaluation in a larger patient cohort with
cardiac syndrome X.
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